How far are we from finding a cure for hepatitis B? We are close, said Timothy Block, PhD, president and co-founder of the Hepatitis B Foundation and its research arm, the Baruch S. Blumberg Institute.

The correlation between portal hypertensive gastropathy and portal hypertension was strong enough to suggest which patients with these conditions could develop cirrhosis, but not hepatocellular carcinoma, according to research published in BMC Gastroenterology.

Your daily antiviral pill can save your life when you have liver damage from chronic hepatitis B. Entecavir or tenofovir quickly reduce the amount of virus in your liver and the damage it causes.

Apart from lifestyle changes and weight loss, there are currently no effective or safe treatments for non-alcoholic fatty liver disease. Now, for the first time, researchers find that a protein called cdk4 occurs at higher levels in mouse models and human patients with the disease. Also, when they blocked the protein in mice, using drugs, it significantly reduced development of hepatic steatosis - the first stage of the disease.

Fatty liver is shorthand for nonalcoholic fatty liver disease. Also shortened to NAFLD, it is called "nonalcoholic" to separate it from a similar liver disease caused by too much alcohol.

The combination drug elbasvir/grazoprevir (Zepatier, Merck) reduced viral load in patients with chronic hepatitis C virus (HCV) infection being treated for opioid addiction in a randomized controlled trial.

Sequential therapy posed a high risk of emergence of multidrug resistance and presented a management issue in chronic hepatitis B (CHB) treatment. We evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug-resistant (MDR) CHB patients.

(Reuters Health) - For teens with non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea and nocturnal hypoxia may worsen scarring in the liver, according to a new study.

NEW YORK (Reuters Health) - Hepatitis C virus (HCV) RNA persists in two-thirds of liver explants from patients who were treated with interferon-free regimens, researchers report.

At the 69th World Health Assembly, the governments of 194 countries unanimously voted to adopt the first Global Viral Hepatitis Strategy, which sets the goal of eliminating viral hepatitis B and C by 2030. The strategy involves prevention and treatment targets which, if reached, will lessen annual deaths by 65% and increase treatment to 80%, saving an estimated 7.1 million lives worldwide by 2030.